Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics.
J Int Med Res
; 51(1): 3000605231153764, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2223990
ABSTRACT
By the end of 2022, there had been a reduction in new cases and deaths caused by coronavirus disease 2019 (COVID-19). At the same time, new variants of the severe acute respiratory syndrome coronavirus 2 virus were being discovered. Critically ill patients with COVID-19 have been found to have high serum levels of proinflammatory cytokines, especially interleukin (IL)-6. COVID-19-related mortality has been attributed in most cases to the cytokine storm caused by increased levels of inflammatory cytokines. Dexamethasone in low doses and immunomodulators such as IL-6 inhibitors are recommended to overcome the cytokine storm. This current narrative review highlights the place of other therapeutic choices such as proteasome inhibitors, protease inhibitors and nuclear factor kappa B inhibitors in the treatment of patients with COVID-19.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
COVID-19
Tipo de estudio:
Revisiones
Tópicos:
Variantes
Límite:
Humanos
Idioma:
Inglés
Revista:
J Int Med Res
Año:
2023
Tipo del documento:
Artículo
País de afiliación:
03000605231153764
Similares
MEDLINE
...
LILACS
LIS